Fig. 3

Recombinant sHSPB5-Fc exhibits anti-apoptosis activity. A, mLEC cells were incubated with 10 μM cisplatin alone or 10 μM cisplatin together with 50 and 100 μg/ml sHSPB5-Fc or human IgG (used as a control) for 24 h. The cleaved Caspase 3 was immunoblotted. B, Quantification of cleaved Caspase 3 in A with Image J. The quantification of cleaved Caspase 3 versus β-actin was accounted for the relative levels of Caspase 3 activity. C, The cells were treated in same way as in A, the cells were stained with FITC-Annexin-V and PI followed by analysis in flow cytometry. The apoptosis percent was shown in Q2 and Q3. The percentage of Q3 means the early apoptotic cells and that of Q2 means the late apoptotic cells. D, sHSPB-5-Fc attenuates UVB-induced cell apoptosis in vitro. mLEC cells were treated with 3 J/m³ UVB (lanes 2–6) followed by recovery in complete media alone (lane 2) or in media containing 50 or 100 μg/ml sHSBP5-Fc (lanes 3 and 5) or human IgG as negative control (lanes 4 and 6) for 24 h. The activated caspase 3 was immunoblotted. E, Quantification of cleaved Caspase 3 in (D) with Image J. The quantification of cleaved Caspase 3 versus β-actin was accounted for the relative levels of Caspase 3 activity. The data were from three independent experiments. Student’s t-test was used for statistical analysis. **p < 0.01, ***p < 0.0001